Hyper-CVAD/MA治疗复发或难治性弥漫大B细胞淋巴瘤的临床研究

The Efficacy and Safety of Hyper-CVAD/MA Regimen in the Treatment of Recurrent or Refractory Diffuse Large B-cell Lymphoma

目的:探讨Hyper-CVAD/MA方案治疗复发或难治弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)的疗效及安全性。方法:观察26例经系统化疗后复发或难治的DLBCL患者接受Hyper-CVAD/MA方案化疗,21-28天为1周期,连续2个周期评价疗效及安全性,分析生存情况。结果:全组26例患者中,总有效率为46.15%,其中完全缓解(complete remission,CR)3例(11.54%),部分缓解(partial remission,PR)9例(34.61%),全组患者中位生存时间为10(2-25)个月,1年和2年总生存率分别为28.57%、14.29%。不良反应主要表现为III-IV度骨髓抑制及继发的肺部感染,其他包括胃肠道反应、口腔炎、肝功能异常等。结论:Hyper-CVAD/MA治疗复发难治DLBCL有一定的疗效,且患者可耐受,可作为二线方案的一个选择。

Objective： To evaluate the clinical efficacy and safety of Hyper-CVAD/MA regimen in patients with recurrent or refractory diffuse large B-cell lymphoma（DLBCL）. Methods： All 26 patients with recurrent or refractory DLBCL were treated with Hyper-CVAD/MA regimen after routine treatment. 21-28 days consisted of one cycle, and the therapeutic efficacy and adverse effect were observed after two cycles. Results： In 26 cases, the overall response rate was 46.15 %. Three patients（11.54 %） achieved a complete remission and 9（34.61 %） achieved a partial remission. The median time of the OS（overall survival） was 10 months. The one-year OS rate and two-year OS rate were 28.57 % and 14.29 %, respectively. Myelosuppression and infection were the major adverse reaction.Other side effects included gastroenteric reactions, oral mucosa inflammation, damage of live function was also observed. Conclusions：Hyper-CVAD/MA regimen can achieve a satisfied result in the treatment of recurrent or refractory DLBCL, and the toxicity was tolerable.